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Thromboembolic events are the leading cause of morbidity and mortality worldwide. From 
the second half of the 20th century, vitamin K antagonists (VKAs), warfarin and acenocoumarol, 
were the only anticoagulants taken orally. The major reform in anticoagulation therapy was made 
by the advent of direct oral anticoagulants (DOACs), about 10 years ago. Direct thrombin 
inhibitor (dabigatran) and direct inhibitors of factor Xa (rivaroxaban, apixaban, edoxaban, and 
betrixaban) have demonstrated favorable risk/benefit ratio. Compared to warfarin, DOACs are 
associated with a predictable pharmacokinetic profile, lower severe bleeding complications, 
particularly intracranial hemorrhages, and minimal drug interactions. Moreover, DOACs achieve 
a rapid onset of action and have shown comparable efficacy with warfarin and low molecular 
weight heparin (LMWH) in clinical trials. As a result, DOACs are now replacing VKAs and 
LMWH for many indications including stroke and systemic embolism prevention in nonvalvular 
atrial fibrillation, prevention, and treatment of venous thromboembolism and thromboprophylaxis 
following total knee/hip replacement surgery. In addition, rivaroxaban (in combination with 
aspirin alone or aspirin and clopidogrel) is used in the prevention of atherothrombotic events 
following acute coronary syndrome with elevated cardiac biomarkers. In case of severe bleeding 
complications under DOACs treatment, antidotes are available; idarucizumab for dabigatran 
reversal and andexanet alfa for rivaroxaban and apixaban. 
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Nonvalvular atrial fibrillation (NVAF) and acute venous thromboembolism (VTE) 
are associated with significant morbidity and mortality. Atrial fibrillation is the most 
prevalent treated arrhythmia, with 33.5 million patients worldwide, and its prevalence is 
increasing, making this a global epidemic (1). Venous thromboembolism (VTE), 
including deep vein thrombosis (DVT) and pulmonary embolism (PE), comes right after 
a heart attack and stroke as a leading cardiovascular diagnosis (2). It is estimated that one 
in four deaths worldwide comes as a result of thrombosis (3). 
Therefore, given the burden of these diseases, the treatment of thromboembolic 
events is a great medical challenge. Anticoagulation therapy is a mainstay for the 
prevention and therapy of VTE and prevention of cardioembolism in AF or patients with 
valvular heart disease. Rapidly acting parenteral anticoagulants have been used for 
prevention and initial treatment of thrombosis, whereas oral agents have been used for 
long-term therapy (4). 
For more than 50 years, warfarin and acenocoumarol, vitamin K antagonists 
(VKAs) have been the gold standard in oral anticoagulation therapy. Albeit they are 
effective, VKAs have numerous limitations. These drugs have a narrow therapeutic range, 
slow onset and offset of action, predisposition to drug and dietary interactions and need 
for frequent monitoring of the international normalized ratio (INR) (5). These 
disadvantages of VKAs led to the development of new oral anticoagulants (non-vitamin 
K antagonists or direct oral anticoagulants) (6).  
Direct oral anticoagulants (DOACs) represent novel direct-acting medications that 
directly inhibit one activated coagulation factor, which is thrombin for dabigatran and 
factor Xa for rivaroxaban, apixaban, edoxaban, and betrixaban (7). Compared with VKAs 
and low molecular weight heparin (LMWH), non-vitamin K antagonists are more 
convenient for administration. Unlike VKAs, they can be given in fixed doses with no 
necessity for routine monitoring of coagulation and are not invasive as LMWH (8, 9). 
Moreover, DOACs were found to be at least as effective as VKAs with less serious 
bleeding events compared to warfarin in the treatment of NVAF and for the treatment of 
VTE (10, 11).  
Owing to their convenience of use, safety profile, comparable efficacy with VKAs, 
and LMWH, DOACs are changing the landscape of anticoagulation therapy.  However, 
as the market is supplied with a wide variety of agents, it could be quite challenging to 
choose the most appropriate DOAC. Therefore, in this work, representatives of DOACs, 






Indications for the DOACs 
The approved indications and dosage regimens of DOACs are listed in Table I. 
 
Table I  Indication and dosage regimens of DOACs (12,13)  
Tabela I  Indikacije i režim doziranja DOAK-a (12,13) 
 
 Dabigatran Rivaroxaban Apixaban Edoxaban 




Prevention of stroke 
and systemic 
embolism in NVAF 
 
 
150 mg bid; 
 
110 mg bid in patients with 
moderate renal impairment 
(CrCl 30-50 ml/min),          





20 mg od; 
 
15 mg od in patients with 
moderate renal impairment   
(CrCl 15–49 mL/min); 
 
Taken with the evening 
meal 
5 mg bid; 
 
2.5 mg bid in patients with 
at least 2 of 3: age ≥ 80yr,    
weight ≤ 60kg;            
SCr ≥ 15 mg per 100 ml; 
 
2.5 mg in patients with 
severe renal impairment     
(CrCl 15-29 mL/min) or 
with strong CYP3A4/P-gp 
inhibitors 
 
30 mg od in patients with 
weight < 61 kg or with 
cyclosporin,  
erythromycin, or in 
patients with renal 
impairment              
(CrCl 15-50 mL/min); 
 
60 mg od in patients with 
weight ≥ 61 kg 
 
 
Treatment of DVT 
and PE and 
prevention of 
recurrent DVT        
and PE 
150 mg bid; 
 
110-150 mg bid in patients 
with age: 75-79 yr or 
moderate renal impairment; 
 
110 mg bid in patients with  
age ≥ 80yr;                  
with P-gp inhibitors 
 




15 mg bid for 21 days, then 
20 mg od (reduction to      
15 mg after evaluating for 
bleeding risk and renal 
impairment) 
 






10 mg bid for 7 days, then 
maintenance 5 mg bid 
 
 
30 mg od in patients with 
weight < 61 kg or with 
cyclosporin,  
erythromycin or in 
patients with renal 
impairment              
(CrCl 15-50 mL/min); 
 
60 mg od in patients with 
weight ≥ 61 kg 
after 5 days treatment with 









110 mg 1-4h after surgery, 
then 220 mg od (10 days for 
knee, 28-35 days for hip); 
 
75 mg 1-4h after surgery, 
then 150 mg od (10 days for 
knee, 28-35 days for hip) in 
patients with moderate renal 
impairment or age ≥ 75yr or 
with P-gp inhibitors 
10 mg od 6-10h after 
surgery (5 weeks for hip, 
12-14 days for knee); 
Taken with the evening 
meal 
 
not recommended in 





2.5 mg bid 12-24h after 
surgery (32-38 days for 












2.5 mg bid with ASA or 






ACS = acute coronary syndrome, CrCl = Creatinine clearance, bid = twice daily, od = once 






Dabigatran etexilate was the first approved DOAC; it was approved by the 
European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 
2008 and 2010, respectively (14, 15). It is a small molecule, prodrug of dabigatran, 
competitive and reversible direct thrombin inhibitor that prevents the conversion of 
fibrinogen to fibrin, thereby preventing clot formation (16).  
Pharmacokinetic profile. After oral administration takes place, dabigatran etexilate 
is rapidly absorbed and completely converted to dabigatran via esterase-catalyzed 
hydrolysis in plasma and liver. The absolute oral bioavailability of dabigatran is 
approximately 3-7% with no impact from food intake. It is formulated as a hard capsule 
filled with pellets coated with dabigatran etexilate mesylate. When the pellets are 
administered without the capsule shell, the oral bioavailability of dabigatran is increased 
by 75% (13,16). Therefore, patients should be advised not to take medication without the 
capsule shell. Dabigatran plasma protein binding is relatively low (35%). Its elimination 
is occasioned predominantly via renal excretion of the unchanged drug (80%) (17).  
Pharmacokinetic characteristics of dabigatran etexilate are displayed in Table II. 
Potential drug interactions. Dabigatran does not inhibit cytochrome P450 (CYP), 
but it is a substrate for P-glycoprotein (P-gp) (16). Hence, there is a potential for 
interaction when it is coadministered with P-gp inhibitors/inducers. Concomitant use of 
dabigatran and some strong inhibitors of P-gp (e.g. cyclosporin, itraconazole) may 
increase plasma dabigatran concentrations to a clinically relevant degree, which may lead 
to an increased bleeding risk. Thus, these combinations are contraindicated (13). Mild to 
moderate inhibitors of P-gp (e.g. amiodarone, posaconazole, ticagrelor, and verapamil) 
and dabigatran ought to be administered with caution. Dosage adjustment of dabigatrane 
etexilate is required when it is used with verapamil. Concomitant use of dabigatran 
etexilate with P-gp inducers (e.g. carbamazepine, phenytoin, rifampicin, hypericum) 
should be avoided (16).  
Efficacy of dabigatran etexilate. In the RE-LY (prospective, randomized, open-
label, multicenter study including 18113 patients), dabigatran etexilate (110 mg or 150 
mg twice daily intake), confirmed efficacy in the prevention of stroke and systemic 
embolism in patients with NVAF compared to warfarin. Higher dose significantly 
reduced risk of stroke and systemic embolism by 35% compared to warfarin (the 
incidence was 1.11% with dabigatran vs 1.71% with warfarin). Intracranial haemorrhage 
was significantly lower with dabigatran 150 mg in comparison to warfarin but major 
gastrointestinal (GI) bleeding was increased by 50% compared to warfarin. A lower dose 
of dabigatran was shown to be non-inferior compared to warfarin in reducing stroke and 
systemic embolism with a 20% lower incidence of major bleeding events whilst the risk 
of major GI bleeding was similar to that of warfarin (18,19). The major bleeding is 




area/organ (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or 
pericardial, or intramuscular with compartment syndrome), or a hemoglobin fall of 2 g/dL 
(1.24 mmol/L) or more (20). Both dabigatran doses resulted in a non-significant 
numerical increase in the rate of myocardial infarction (MI) (18, 19). Although this has 
not been confirmed in real-world data, it might not be the best option for patients with an 
increased risk of MI (21). The safety outcomes of RE-LY study are listed in Table III. 
In the RE-COVER and RE-COVER II (two double-blind randomized, multicenter 
studies including 5153 patients) dabigatran was used in patients with acute VTE and was 
proved to be equally efficacious compared to warfarin in the prevention of recurrent VTE 
or VTE related to death. The rate of major bleeding was 0.9% with dabigatran in 
comparison to 1.8% with warfarin (22).  
In the large, randomized, double-blind trials, RE-MODEL, RE-NOVATE and RE-
NOVATE II (including 2076, 3494 and 2055 patients respectively) dabigatran etexilate 
and enoxaparin were found to be equally efficacious in patients undergoing hip/knee 
replacement surgeries. In addition, there were no significant differences in terms of the 
bleeding complications between the groups. Furthermore, the cost-utility analysis 
indicated that dabigatran etexilate 220 mg once daily intake was not only effective but 
also economically more favorable in comparison to enoxaparin (23). 
Adverse effects and contraindications. Dabigatran etexilate is generally well 
tolerated. The most common adverse effects of dabigatran are dyspepsia (>10%), 
dizziness, dyspnea, and peripheral oedema (13,16). However, the rate of GI bleeding is 
significantly higher with dabigatran compared to warfarin (16). General contraindications 
for all antithrombotic drugs are active bleeding and risk factors for major bleeding.  
Manufacturers advise for all DOACs to be avoided during pregnancy/breastfeeding. 
DOACs are not recommended for patients with a history of thrombosis who are diagnosed 
with antiphospholipid syndrome. In particular, for patients that are triple positive (for 
lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies), 
treatment with DOACs could be associated with increased rates of recurrent thrombotic 
events compared with vitamin K antagonist therapy. Besides, caution is needed if DOACs 
are used with other anticoagulants or drugs affecting bleeding, including NSAIDs and 
antiplatelet drugs (13). In particularly, dabigatran is contraindicated in patients with 
severe renal impairment (creatinine clearance (CrCl) < 30 mL/min) (13). In 2015, 
idarucizumab, a specific reversal agent for dabigatran was approved by EMA in case of 
life-threatening bleeding or before emergency surgery (24).  
Rivaroxaban 
Rivaroxaban was the first direct oral factor Xa inhibitor receiving the authorization 
for clinical use in 2008 by EMA (25). It is the only DOAC which has as official indication 




elevated cardiac biomarkers (in combination with aspirin alone or aspirin and 
clopidogrel) (26).  
Pharmacokinetic profile. Rivaroxaban is absorbed rapidly and almost completely. 
The absolute bioavailability is relatively high (80-100%) with the 10 mg tablet dose, 
independently on fasting or fed conditions. In contrast, the rate of absorption and 
bioavailability of higher doses decrease without food (25). Therefore, tablets of 
rivaroxaban higher doses (15 or 20 mg) should be administered with food. Binding to the 
plasma proteins reaches about 92-95% (27). Approximately 28% of the drug is excreted 
in the feces and about 66% via the kidneys; 33% as unchanged drug and the remainder as 
inactive metabolites (28). Pharmacokinetic characteristics of rivaroxaban are listed in 
Table II. 
Potential drug interactions. Rivaroxaban is metabolized in the liver by CYP-P450 
isoenzyme CYP3A4 and is a substrate for P-gp (27). Therefore, concomitant use with 
drugs interfering with CYP3A4/P-gp may influence exposure to rivaroxaban. 
Coadministration of rivaroxaban with strong CYP3A4 and P-gp inhibitors (e.g. 
itraconazole, HIV-protease inhibitors) is not recommended due to significantly increased 
exposure to rivaroxaban and consequently increased bleeding risk (13). Concomitant use 
of rivaroxaban with strong P-gp and CYP3A4 inducers (e.g. rifampin, phenytoin, 
carbamazepine, hypericum) ought to be used with caution (27). In patients with renal 
failure, coadministration of P-gp and weak/moderate CYP3A4 inhibitors (e.g. verapamil, 
amiodarone, diltiazem, azithromycin, and erythromycin) should be considered using only 
if benefits outweigh the possible risks (29).  
Efficacy of rivaroxaban. In the ROCKET-AF (double-blind, prospective, 
multicenter study including 14264 patients with NVAF), rivaroxaban was compared with 
warfarin in the prevention of stroke and systemic embolism in patients with NVAF. 
Rivaroxaban reduced stroke or systemic embolism by 21% compared to warfarin (the 
incidence was 2.1% with rivaroxaban vs 2.4% with warfarin). There was a significant 
reduction in intracranial haemorrhage (the rates were 0.5% vs 0.7%) but an increase in 
major GI bleeding events (the rates were 2.0% vs 1.24%) compared to warfarin (30). The 
safety outcomes of ROCKET-AF study are listed in Table III. 
In EINSTEIN DVT and EINSTEIN PE (randomized, open-label multicenter studies 
including 3449 and 4845 patients, respectively), the efficacy and safety of rivaroxaban 
were compared to LMWH/VKA for the acute treatment of symptomatic DVT and PE, 
respectively. Rivaroxaban demonstrated similar efficacy (the rate of VTE recurrence was 
2.1% with rivaroxaban vs 2.3% with LMWH/VKA) compared to traditional treatment of 
VTE and was associated with significantly less major bleeding events (the incidence was 
1.0% vs 1.7%) (28).  
The four randomized, double-blind, multicenter trials including 12729 patients in 




for VTE prevention after total hip/knee arthroplasty. Rivaroxaban was proved to be as 
effective as enoxaparin with low major bleeding events indicating it may be used instead 
of traditional parenteral therapy in patients undergoing major orthopaedic surgeries (28). 
SELECT-D trial (randomized, multicenter, open-label, pilot trial including 406 
patients) compared the efficacy of rivaroxaban with dalteparin in patients with active 
cancer and VTE. Active cancer is defined as a diagnosis of cancer (excluding basal-cell 
or squamous-cell skin carcinoma) in the previous 6 months, recurrent or metastatic 
cancer, or cancer not in complete remission (hematologic malignancy). Rivaroxaban 
showed a beneficial effect with regard to VTE recurrence comparing to dalteparin, the 
rate was 4% with rivaroxaban and 11% with dalteparin. The major bleeding was 6% with 
rivaroxaban and 4% with dalteparin, followed by significantly higher clinically relevant 
non-major (CRNM) bleeding with rivaroxaban compared to dalteparin, 13% and 4%, 
respectively.  CRNM bleeding is defined as any sign or symptom of bleeding that is not 
considered as major bleeding but does include one of the following: requirement for 
medical intervention, leading to hospitalization or need for a face to face evaluation (i.e. 
not just telephone or electronic communication) (20). Major bleeding was higher in 
patients with esophageal or gastroesophageal cancers with rivaroxaban than with 
dalteparin, 36% and 11% respectively. Therefore, in patients with GI cancer (particularly 
with esophageal or gastroesophageal cancers), LMWH remains the first-line option (31). 
Adverse effects and contraindications. The most common side effect is bleeding. 
Rates of major and CRNM bleeding were no different between warfarin and rivaroxaban, 
but there were more GI bleeds with rivaroxaban compared to warfarin. Nausea and 
increases in liver enzyme values may also occur; other GI effects, pruritus, rashes, and 
renal impairment have been reported but are uncommon (0.1% to 1%) (13). There are no 
data available for rivaroxaban use in patients with CrCl <15 mL/min, and it is not 
recommended in this patient group, it is also contraindicated in patients with hepatic 
disease and clinically significant active bleeding or conditions that constitute a major 
bleeding risk (28). In April 2019, EMA approved andexanet alfa for management of life-













Table II  Pharmacokinetic characteristics of DOACs (9,13,41) 
Tabela II  Farmakokinetičke karakteristike DOAK-a (9,13,41) 
 
Characteristics Dabigatran Rivaroxaban Apixaban Edoxaban Betrixaban 
Target Thrombin (IIa) Factor Xa Factor Xa Factor Xa Factor Xa 
Bioavailability 3-7% 
15 mg/20 mg:       
66% without food,   
80–100% with 
food 
50% 62% 34% 
Time to peak 
activity 
0.5-2 h 2-4 h 3-4 h 1-2 h 3-4 h 
Half-life 12-17 h 7-11 h 12 h 10-14 h 19-27 h 
Protein binding 35 % 92-95% 87% 55% 60% 
Dosing frequency Twice daily 
Once or Twice 
daily 
Twice daily Once daily Once daily 
Drug interactions P-gp CYP3A4/P-gp CYP3A4/P-gp P-gp P-gp 
Renal elimination 80% 33% (66%) 27% 35% 17.8% 
Apixaban 
Apixaban is the third DOAC approved by EMA in 2011 (33). It is a reversible direct 
factor Xa antagonist. In July 2020, generic versions of apixaban were approved by EMA 
(34). 
Pharmacokinetic profile. Apixaban is rapidly absorbed after oral administration 
and its bioavailability is approximately 50% with a dose up to 10 mg (35). However, for 
oral doses ≥ 25 mg, absorption is dissolution-limited and bioavailability is reduced. 
Apixaban may be taken on an empty or full stomach (35). The plasma protein binding of 
apixaban is approximately 87%. Compared with other DOACs, apixaban is to a smaller 
extent eliminated by the kidneys (~27%) and might be an optimal choice by clinicians in 
patients with modest renal impairment (36). Pharmacokinetic characteristics of apixaban 
are listed in Table II. 
Potential drug interactions. Apixaban is predominantly metabolized by CYP3A4 
isoenzyme and is also a substrate for P-gp transporter proteins (13). Concomitant use with 
strong dual inhibitors of CYP3A4 and P-gp (e.g. itraconazole, voriconazole, 
posaconazole, ritonavir or clarithromycin) increases apixaban exposure and risk of 
bleeding and is not recommended in the EU (35). Concomitant use of apixaban with 
strong inducers of CYP3A4 and P-gp (e.g. rifampicin, phenytoin, carbamazepine, 
phenobarbitone) is not recommended as may decrease the efficacy of the anticoagulant 
agent. Administration of activated charcoal can decrease apixaban concentration by 50% 
when given 2 hours after a single dose of apixaban and may be used in the management 




Efficacy of Apixaban. In the ARISTOTLE (randomized, double-blind, multicenter, 
trial including 18 201 patients), apixaban (5 mg twice daily) reduced stroke or systemic 
embolism in patients with NVAF by 21% compared with warfarin (the rate of stroke and 
systemic embolism was 1.27% with apixaban compared to 1.6% with warfarin). On the 
other hand, the safety profile was also more favorable with apixaban, there was a 31% 
reduction in major bleeding compared to warfarin (the rate was 2.13% with apixaban vs 
3.09% with warfarin), in particular with intracranial haemorrhage (0.33% vs 0.80%) and 
haemorrhagic stroke (0.24% vs 0.47%) (37,38). Additionally, one of the advantages over 
other DOACs was less GI bleeding events. Rates of major GI bleeding were similar 
between two treatments (0.76% with apixaban vs 0.86% with warfarin) indicating 
apixaban may be preferred over dabigatran and rivaroxaban in patients with the risk of 
GI bleeding (38). The safety outcomes of ARISTOTLE study are listed in Table III. 
In AMPLIFY (randomized, double-blind, study including 5395 patients), apixaban 
demonstrated to be non-inferior to traditional anticoagulant therapy (enoxaparin 
overlapped with and followed by warfarin) in the treatment of adults with acute VTE over 
6 months. Additionally, apixaban was shown to be safer compared with 
enoxaparin/warfarin with a significantly lower incidence of major and the CRNM 
bleeding (35).  
In ADVANCE, randomized double-blind multicenter clinical trials, including 8464 
patients undergoing knee/hip replacement surgery, apixaban was found to be more 
effective compared to enoxaparin without increased incidence of bleeding (39).  
CARAVAGGIO trial (prospective, randomized, open-label clinical trial including 
1168 patients) compared apixaban with dalteparin in patients with cancer and acute 
proximal DVT and/or PE. The recurrence of VTE was 5.6% with apixaban and 7.9% in 
dalteparin group. The rate of major bleeding was 3.8% in the apixaban group and 4.0% 
in the dalteparin group whereas the incidence of major GI bleeding was 1.9% with 
apixaban compared to 1.7% with dalteparin (40). This implies apixaban might be safe 
enough to be used in patients with GI cancer but further studies are needed to confirm 
this. 
Adverse effects and contraindications. The same as with other anticoagulants, the 
most serious and potentially life-threatening adverse effect of apixaban is bleeding. In 
clinical trials, apixaban has shown superiority to enoxaparin/warfarin concerning the risk 
of major bleeding (35). Other common side effects (with incidence 1% to 10%) besides 
bleeding include nausea, anemia, an increase in liver transferases/transaminases and skin 
reactions (33). In case of life-threatening or uncontrolled bleeding, EMA approved 





Edoxaban was the third approved oral direct factor Xa inhibitor, initially approved 
in Japan in 2011, following by EMA and FDA approval in 2015 (41,42). It has been 
approved for two indications in Europe: prevention of stroke and systemic embolism in 
adult patients with NVAF with one or more risk factors and treatment/prevention of DVT 
and PE in adults (43). In Japan, edoxaban is also indicated for VTE prevention in patients 
undergoing hip fracture surgery (41).  
Pharmacokinetic profile. Edoxaban demonstrated linear pharmacokinetics at the 
therapeutic doses. It is rapidly absorbed (1-3 hours) with an oral bioavailability of 
approximately 61.8% (41). It can be taken with or without food. The majority of the drug 
(73%) is eliminated unchanged via urine (35%) and feces (62%). Interestingly, edoxaban 
is associated with a lower relative efficacy in patients with NVAF compared with warfarin 
in patients with a CrCl > 95 mL/min. Because of this, EMA suggests using edoxaban in 
patients with high CrCl after a careful evaluation of the risk/benefit ratio (9). 
Pharmacokinetic characteristics of edoxaban are listed in Table II.   
Potential drug interactions. In contrast with rivaroxaban and apixaban, edoxaban 
is minimally metabolized by CYP3A4 (<4%) (44). Therefore, the risk of potential 
interactions of edoxaban with other drugs is low. However, edoxaban is a substrate for P-
gp and thus not completely devoid of potential drug interactions. Consequently, when 
administered with potent P-gp inhibitors (e.g. itraconazole, voriconazole, erythromycin) 
dose should be halved. By contrast, when administered with amiodarone or verapamil, no 
dose adjustment is required. Edoxaban can be safely taken with itraconazole or 
voriconazole (by halving the dose) (44).  
 Efficacy of Edoxaban. In the ENGAGE AF-TIMI 48 (a randomized, double-blind 
multicenter clinical trial including 21105 patients), edoxaban (60 mg and 30 mg once 
daily) was proved to be non-inferior compared to warfarin in the prevention of stroke and 
systemic embolism in patients with NVAF (the stroke and systemic embolism occurred 
in 1.29% patients with warfarin vs 1.00% and 1.79% with edoxaban, 60 mg and 30 mg, 
respectively). Moreover, the higher dose of edoxaban significantly reduced major 
bleeding events by 20% compared with warfarin, whilst the lower dose significantly 
reduced major bleeding events by 53% (45). The safety outcomes of ENGAGE AF-TIMI 
48 study are listed in Table III. 
The Hokusai-VTE (randomized, double-blind, multicenter study including 8292 
patients) examined the efficacy and safety of edoxaban for the treatment of VTE 
compared with warfarin after the initial course with heparin. This study found that 
edoxaban is as effective as warfarin with a better safety profile for the treatment of VTE 
(46). 
Hokusai VTE Cancer trial (randomized, open-label, multicenter clinical trial 




once daily) with subcutaneous dalteparin (200 IU/kg once daily for 1 month, then 150 
IU/kg once daily) in cancer patients with proximal DVT, acute symptomatic or incidental 
PE for 6-12 months. Edoxaban has shown similar efficacy and safety compared to 
dalteparin. The incidence of VTE recurrence was 7.9% with edoxaban compared to 11.3% 
with dalteparin. The rate of major bleeding was 6.9% with edoxaban and 4% with 
dalteparin. This difference is mainly because of the higher upper GI bleeding with 
edoxaban, predominantly seen in GI cancer patients (47). Therefore, in patients with GI 
cancer, edoxaban should be avoided. 
Adverse effects and contraindications. Besides bleeding, other common adverse 
effects (with incidence 1% to 10%) are anemia, nausea, skin reactions (12).  
Betrixaban 
Betrixaban is the last DOAC, direct Xa inhibitor available, approved in 2017 by the 
FDA for extended thromboprophylaxis in hospitalized acute medically ill patients at risk 
of VTE; it has not been approved in the EU yet (48).  
Pharmacokinetic profile. Betrixaban has rather different pharmacokinetic 
properties from other DOACs, particularly with regard to low renal clearance and 
minimal metabolism by CYP enzymes. Betrixaban is rapidly absorbed, with a 
bioavailability of approximately 34% and peak plasma concentration after 3–4 h. 
Bioavailability is lowered when taken with fatty food. The plasma protein binding of 
betrixaban is approximately 60%. It has the longest half-life compared with other 
DOACs, therefore it is administered once daily. Betrixaban is primarily excreted in the 
gut (85%), mostly unmetabolized (49). Pharmacokinetic characteristics of betrixaban are 
listed in Table II. 
Potential drug interactions. Opposite to apixaban and rivaroxaban, betrixaban has 
a minimal metabolism by CYP enzymes (<1%) and does not induce/inhibit CYP-P450 
activity. As betrixaban is a substrate for P-gp, concomitant use with P-gp inhibitors (e.g., 
amiodarone, azithromycin, verapamil, clarithromycin) carries increased bleeding risk and 
in that case, a dose of betrixaban should be reduced (48,49).  
Efficacy of Betrixaban. Betrixaban has a long half-life, low renal elimination, and 
minimal metabolism by CYP enzymes making it especially convenient for the acute 
medically ill patients. Furthermore, it is not contraindicated in patients with severe renal 
impairment (dose reduction indicated) and has a low predisposition for drug interactions 
(dose reduction indicated for patients on P-glycoprotein inhibitors) (49). 
In the APEX, randomized, multicenter clinical trial (including 7513 patients), 
betrixaban was compared with a standard enoxaparin regimen for thromboprophylaxis in 
patients hospitalized with an acute medical illness. Patients were included in the trial if 
they were 40 years of age or older, had been hospitalized for less than 96 hours for a 




for VTE. Oral betrixaban administered over approximately 40 days was found to be more 
effective comparing to subcutaneous enoxaparin administered over approximately 10 
days. The risk of major bleeding was similar between the two drugs; however, the 
combined risk of major bleeding and CRNM bleeding was higher with betrixaban (48). 
 
Table III  Safety comparison of DOACs with warfarin in patients with NVAF (54) 










(ENGAGE              
AF-TIMI 48) 







No. of patients 18113 14264 18201 21105 
Duration (years) 2 1.9 1.8 2.8 
Randomized groups 
warfarin vs. dabigatran           
(150 mg bid, 110 mg bid) 
warfarin vs. rivaroxaban   
20 mg od 
warfarin vs. apixaban       
5 mg bid 
warfarin vs. edoxaban 
(60 mg od, 30 mg od) 









































































MB 3.61 3.40 2.92 3.45 3.60 3.09 2.13 3.43 2.75 1.61 
ICB 0.77 0.32 0.23 0.74 0.49 0.80 0.33 0.85 0.39 0.26 
GI MB 1.09 1.60 1.13 1.24 2.00 0.86 0.76 1.23 1.51 0.82 
MI 0.64 0.81 0.82 1.12 0.91 0.61 0.53 0.75 0.70 0.89 




4.13 3.64 3.75 2.21 1.87 3.94 3.52 4.35 3.99 3.80 
MB = Major bleeding; ICB = Intracranial bleeding; GI MB = Gastrointestinal major 
bleeding; MI = Myocardial infarction; HS = Haemorrhagic stroke; od = once daily; bid = twice 
daily 
 
Concomitant use of antiplatelet agents and DOACs in patients with 
NVAF and coronary artery disease 
Given the fact that patients with AF often have an acute coronary syndrome (ACS) 




antiplatelet agents and oral anticoagulants is often inevitable (50). Until recently, 
common guidelines for patients with AF and ACS or undergoing PCI, recommended the 
use of three medications in so-called triple therapy which include dual antiplatelet therapy 
(DAPT) – aspirin and clopidogrel combined with oral anticoagulation therapy, usually 
VKA for 6 months followed by a combination of VKA and one antiplatelet agent up to 
12 months, after which lifelong therapy with VKA ought to be continued (50). Recently, 
there has been published four randomized controlled trial clinical trials (The PIONEER 
AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PC trial) comparing DOACs 
(rivaroxaban, dabigatran, apixaban and edoxaban) with conventional treatment (VKA-
based combination triple therapy) in patients with AF and recent ACS or undergoing PCI. 
The results of these studies showed the similar efficacy between dual therapy (one DOAC 
plus P2Y12 inhibitor) and conventional triple therapy (VKA plus aspirin plus P2Y12 
inhibitor) with significantly less major bleeding (including intracranial haemorrhage) in 
patients with dual therapy (50,51,52,53). It should be noted that both, the PIONEER AF-
PCI and the RE-DUAL PCI trial demonstrated a lower incidence of bleeding with DOACs 
(rivaroxaban and dabigatran) without aspirin than with VKA therapy that included 
aspirin, hence it was not clear whether this result was due to the use of DOACs or to the 
removal of aspirin in therapy (50,51). In the AUGUSTUS trial, placebo (vs aspirin) and 
apixaban (vs VKA) regimens were related to significant reduction in bleeding (52).  
Overview of DOACs – their advantages and disadvantages 
As we mentioned above, DOACs have various advantages over VKAs. They have 
demonstrated equal or even greater efficacy in the treatment of NVAF compared with 
warfarin. In general, DOACs are equally / more effective compared to warfarin in the 
treatment of stroke and systemic embolism, but the main strength of DOACs over 
warfarin is the reduction of intracranial haemorrhage by approximately 50%. In general, 
DOACs significantly reduced events of stroke and systemic embolism by 19% comparing 
to warfarin but the main strength of DOACs over warfarin is the reduction of intracranial 
haemorrhage by approximately 50%. On the other hand, they increased major GI bleeding 
by 24% compared with warfarin (10). DOACs have also demonstrated non-inferior 
efficacy compared to LMWH in the treatment of VTE (11).  As DOACs can achieve a 
rapid onset of action, they can be used in all-oral regimens, thus replacing parenteral 
anticoagulants and warfarin for initial treatment and prevention of VTE. Some guidelines 
(e.g. NICE guidance) suggest using rivaroxaban and apixaban in all-oral regimens, 
obviating the need for a parenteral anticoagulant at the outset, whereas dabigatran and 
edoxaban are administered 5 days after initial treatment with LMWH. In patients with 
VTE and active cancer, new guidelines (NICE 2020) consider DOACs instead of LMWH 
if there is no contraindication for their use (e.g. CrCl < 15 mL/min, antiphospholipid 
syndrome) (55, 56). In addition, it should be emphasized that DOACs ought to be avoided 




on the results of clinical trials. With this wealth of evidence, guidelines give preference 
to the DOACs over VKAs for stroke and VTE prevention/treatment in most patients with 
NVAF and VTE (54, 56).  
One of the advantages of DOACs is that they do not request dose titration and 
requirement for therapeutic monitoring in most patients. However, in some situations, 
(e.g. renal impairment, geriatrics, taking concomitant interfering medications, obesity, the 
need for emergency surgery) laboratory monitoring may be necessary. Laboratory tests 
used for a global assessment of the coagulation (such as activated partial thromboplastin 
time [aPTT], prothrombin time (PT) and INR) can be affected by the DOACs, but their 
levels do not accurately reflect their plasma concentrations. Dabigatran preferentially 
affects the aPTT, while Xa inhibitors preferentially affect PT. However, these tests ought 
to be standardized for their wider clinical use. In addition, owing to their rapid onset/offset 
of action, it is important to correlate laboratory tests with the last drug intake. Unlike 
warfarin, the INR is not suitable for the measurement of the anticoagulant effect of the 
DOACs (8).  
Although DOACs undoubtedly have numerous advantages over VKAs and 
LMWH, they also have some limitations. For example, DOACs are not licensed in 
patients with valvular heart diseases or prosthetic heart valves. The RE-ALIGN study was 
discontinued due to the increased occurrence of thromboembolic and bleeding 
complications in patients with mechanical heart valves taking dabigatran compared with 
warfarin patients (57). In addition, there is a need for avoidance or dose adjustment in 
patients with renal failure or with concomitant use with P-gp/CYP-3A4 
inhibitors/inducers. The short half-life which is in most cases preferable sometimes can 
be undesirable as it requires strict patient adherence (9). A significant issue also remains 
the cost of DOACs. However, as EMA approved the first generics of Eliquis (apixaban) 
tablets, this problem will be solved with the advent of generic drugs on the market in the 
foreseeable future (34). 
As there are several representatives available, choosing adequate medication may 
be demanding. When it comes to deciding which drug to choose, clinicians should take 
into consideration patient comorbidities and individual preferences (Table IV). In patients 
with a history of GI bleeding, apixaban may be the most appropriate choice as it has been 
shown to have a similar or lower incidence of GI bleeding as warfarin (38). Dabigatran 
should be avoided in patients with dyspepsia or peptic ulcer disease, as symptoms can get 
worse (18).  If patients prefer once-daily dosing, rivaroxaban or edoxaban are better 
options especially in patients with poor adherence. In patients with a history of MI, 
dabigatran should be avoided (18). In patients with significant renal impairment, some 
clinicians prefer apixaban over other DOACs because renal elimination may be lower 
with this agent (36). On the other hand, in patients with very high CrCl, edoxaban should 




For instance, concomitant use with CYP3A4 inhibitors/inducers may prevail over 
dabigatran and edoxaban due to their more favorable pharmacokinetic profile (16, 44). 
 
Table IV  Suggestions for the choice of DOACs in patient eligible for them (9)  
Tabela IV  Preporuke za izbor DOAK-a u pacijenata kod kojih su indikovani (9) 
 
Characteristic Drug of choice Rationale 
Recent gastrointestinal (GI) bleed Apixaban 
More GI bleeding with dabigatran, 
rivaroxaban and edoxaban compared 
with warfarin. 
Dyspepsia or upper GI symptoms Rivaroxaban, apixaban or edoxaban 
Dyspepsia may occur in 10% of 
patients treated with dabigatran.
All- oral therapy Rivaroxaban or apixaban 
They are the only DOACs evaluated 
in all-oral regimens.
Creatinine clearance 30-50 
mL/min 
Rivaroxaban, apixaban or edoxaban 
Less affected by renal impairment 
than dabigatran which has a renal 
clearance of 80%.
Creatinine clearance 15-29 
mL/min 
Apixaban 
It has lower renal elimination 
compared to rivaroxaban, edoxaban, 
and dabigatran. 
Recent acute coronary syndrome 
(ACS) 
Rivaroxaban 
Rivaroxaban is the only DOAC 
indicated in the prevention of 
atherothrombotic events following  
ACS. 
Poor compliance with twice-daily 
dosing 
Rivaroxaban or edoxaban They are once-daily used. 
Concomitant use with CYP3A4 
inducers/inhibitors 
 
Dabigatran or edoxaban 
Dabigatran is not metabolized by 
CYP3A4 while edoxaban is 
metabolized to a small extent.
Acute medical illness Betrixaban 
Promising results in patients 
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Tromboembolijski događaji predstavljaju vodeći uzrok morbiditeta i mortaliteta širom 
sveta. Od druge polovine 20. veka, antagonisti vitamina K (VKA), varfarin i acenokumarol bili 
su jedini dostupni oralni antikoagulantni lekovi. Pojava direktnih oralnih antikoagulanasa 
(DOAK), od pre 10-tak godina, donela je veliku promenu u antikoagulantnoj terapiji. Direktni 
inhibitor trombina (dabigatran) i direktni inhibitori faktora Xa (rivaroksaban, apiksaban, 
edoksaban i betriksaban) su pokazali povoljan odnos koristi i rizika. U poređenju sa varfarinom, 
DOAK pokazuju predvidljiv farmakokinetički profil, nižu incidencu ozbiljnog krvarenja posebno 
intrakranijalnog krvarenja i stupaju u mali broj interakcija sa drugim lekovima. Pored toga, 
DOAK imaju brz nastup dejstva i pokazali su komparabilnu efikasnost u poređenju sa varfarinom 
i niskomolekularnim heparinima (LMWH) u kliničkim ispitivanjima. Posledično, DOAK 
postepeno zamenjuju VKA i LMWH u mnogim indikacijama uključujući prevenciju moždanog 
udara i sistemskog embolizma kod pacijenata sa nevalvularnom atrijalnom fibrilacijom, 
prevenciju i terapiju venskog tromboembolizma, kao i tromboprofilaksu nakon ugradnje 
veštačkog kolena/kuka. Dodatno, rivaroksaban (sa aspirinom ili kombinacijom aspirina i 
klopidogrela) je indikovan u prevenciji aterotrombotičnih događaja posle akutnog koronarnog 
sindroma, kod pacijenata sa povećanim srčanim biomarkerima. U slučaju pojave ozbiljnog 
krvarenja, dostupni su antidoti; idarucizumab za dabigatran i andeksanet alfa za rivaroksaban i 
apiksaban.  
 
Ključne reči: direktni oralni antikoagulansi, dabigatran, rivaroksaban, apiksaban,  
  edoksaban, betriksaban 
 
